| ID | 66954 |
| FullText URL | |
| Author |
Nakamura, Keiichiro
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Matsuoka, Hirofumi
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yorimitsu, Masae
Department of Obstetrics and Gynecology, City Hiroshima Citizens Hospital
Ogawa, Mariko
Department of Obstetrics and Gynecology, National Organization Fukuyama Medical Center
Kanemori, Miho
Department of Obstetrics and Gynecology, Fukuyama City Hospital
Sueoka, Kotaro
Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine
Kozai, Ayumi
Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine
Nakamura, Hiroko
Department of Obstetrics and Gynecology, National Hospital Organization KURE Medical Center and Chugoku Cancer Center
Haruma, Tomoko
Department of Obstetrics and Gynecology, Saiseikai General Hospital
Shiroyama, Yuko
Department of Obstetrics and Gynecology, Prefectural Hospital
Hayata, Yuu
Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital
Sugii, Hirokazu
Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni Clinical Center
Ueda, Akiko
Department of Obstetrics and Gynecology, Onomichi General Hospital
Kurihara, Shuichi
Department of Obstetrics and Gynecology, Japanese Red Cross Matsuyama Hospital
Urayama, Saiko
Department of Obstetrics and Gynecology, Higashi Hiroshima Medical Center
Shimizu, Miyuki
Department of Obstetrics and Gynecology, Kagawa Rosai Hospital
Masuyama, Hisashi
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
|
| Abstract | Objective: To investigate whether maintenance treatment could be safely and effectively performed with olaparib, olaparib plus bevacizumab and niraparib in platinum-sensitive advanced ovarian cancer at multiple institutions in Japan.
Methods: We investigated progression-free survival and adverse events in 117 patients with platinum-sensitive advanced ovarian cancer treated with maintenance therapy. Results: The median progression-free survival of 117 patients was 20.1 months. Patients with germline BRCA pathogenic variants had a significantly better prognosis than the other groups (P < 0.001). Furthermore, in the multivariate analysis, stage IV (P = 0.016) and germline BRCA wild-type (P ≤ 0.001) were significantly associated with worse progression-free survival in patients with advanced ovarian cancer. Regarding adverse events, all three types of maintenance treatment were significantly worse than chemotherapy given before maintenance treatment with respect to renal function (olaparib, P = 0.037; olaparib plus bevacizumab, P < 0.001; and niraparib, P = 0.016). Conclusion: Maintenance treatment was performed effectively and safely. Renal function deterioration is likely to occur during maintenance treatment, and careful administration is important in platinum-sensitive advanced ovarian cancer. |
| Keywords | olaparib
olaparib plus bevacizumab
niraparib
renal function
|
| Published Date | 2023-09-14
|
| Publication Title |
Japanese Journal of Clinical Oncology
|
| Volume | volume54
|
| Issue | issue1
|
| Publisher | Oxford University Press (OUP)
|
| Start Page | 31
|
| End Page | 37
|
| ISSN | 1465-3621
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © The Author(s) 2023.
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.1093/jjco/hyad125
|
| License | https://creativecommons.org/licenses/by/4.0/
|
| Citation | Keiichiro Nakamura, Hirofumi Matsuoka, Masae Yorimitsu, Mariko Ogawa, Miho Kanemori, Kotaro Sueoka, Ayumi Kozai, Hiroko Nakamura, Tomoko Haruma, Yuko Shiroyama, Yuu Hayata, Hirokazu Sugii, Akiko Ueda, Shuichi Kurihara, Saiko Urayama, Miyuki Shimizu, Hisashi Masuyama, Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer, Japanese Journal of Clinical Oncology, Volume 54, Issue 1, January 2024, Pages 31–37, https://doi.org/10.1093/jjco/hyad125
|
| Funder Name |
Society of Obstetrics and Gynecology in the Chugoku and Shikoku areas
|
